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Abstract
The Wnt signaling pathway is a robust regulator of skeletal homeostasis. Gain-of-function mutations promote high bone
mass, whereas loss of Lrp5 or Lrp6 co-receptors decrease bone mass. Similarly, mutations in antagonists of Wnt signaling
influence skeletal integrity, in an inverse relation to Lrp receptor mutations. Loss of the Wnt antagonist Sclerostin (Sost)
produces the generalized skeletal hyperostotic condition of sclerosteosis, which is characterized by increased bone mass
and density due to hyperactive osteoblast function. Here we demonstrate that prostaglandin E2 (PGE2), a paracrine factor
with pleiotropic effects on osteoblasts and osteoclasts, decreases Sclerostin expression in osteoblastic UMR106.01 cells.
Decreased Sost expression correlates with increased expression of Wnt/TCF target genes Axin2 and Tcf3. We also show that
the suppressive effect of PGE2 is mediated through a cyclic AMP/PKA pathway. Furthermore, selective agonists for the PGE2
receptor EP2 mimic the effect of PGE2 upon Sost, and siRNA reduction in Ptger2 prevents PGE2-induced Sost repression.
These results indicate a functional relationship between prostaglandins and the Wnt/b-catenin signaling pathway in bone.
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Introduction
There remains considerable effort dedicated toward under-
standing the signaling pathways that promote skeletal anabolism.
Prostaglandins (PG), such as prostaglandin E2 (PGE2), mediate
osteoprogenitor proliferation [1,2,3] and differentiation [4,5].
Mechanical loading in vitro and in vivo induces expression of the
enzyme responsible for PG synthesis, COX-2 [6,7,8], whose
function is required for load-induced bone formation [9,10].
Similarly, PG administration in vivo increases bone mass via
periosteal and endosteal responses [11]. Further, inhibition of PG
synthesis delays fracture healing [12,13] and promotes the
formation of non-unions [14,15], whereas localized PGE2
enhances bone healing [16,17,18,19].
Osteoblast differentiation is also regulated by the Wnt signaling
pathway [20]. Binding of Wnt ligands to a complex of Frizzled and
Lrp5 or Lrp6 co-receptors promotes the stabilization of the
transcription factor b-catenin, formation of a complex with TCF/
LEF, and induction of Wnt target genes like Axin2 and Tcf3
[21,22]. Activating mutations in Lrp5 cause high bone mass
[23,24], whereas Lrp5 deletion decreases bone mass [25,26] and
prevents load-induced bone formation [27]. Control of Wnt
signaling involves sequestration of Wnts by soluble decoy receptors
like sFRPs [28,29], or Lrp5 antagonists, like Dkk1 and Sclerostin.
Deletion of the gene encoding Sclerostin (Sost) causes a rare
sclerosing bone dysplasia, sclerosteosis (OMIM ID 269500) in both
humans and murine knockout models [30,31,32,33]; a related
disease, van Buchem’s disease (OMIM ID 239100), is caused by a
distal noncoding deletion that removes regulatory elements
required for the transcriptional of the Sost gene in adult bone
[32]. Both sclerosteosis and van Buchem disease are characterized
by general skeletal hyperostosis owing to hyperactive osteoblast
activity. In contrast, over-expression of Sost causes osteopenia
[34,35] and limb deformities [36]. Mechanistically, Sclerostin was
initially characterized as a BMP antagonist [34,37,49], but more
recent reports recognize it as a potent Wnt antagonist that binds to
Lrp5 and Lrp6 [38,39,40,41] to increase the rate of receptor
internalization [42]. Keller and Kneissel showed that PTH
reduces Sost expression via PKA [43], as did Bellido et al. [44],
and we have previously demonstrated that the regulatory element
ECR5 contained within the van Buchem deletion region is
necessary for bone-specific Sost expression in transgenic mice [35],
and confers PTH responsiveness, in vitro [45]. Recently, we have
also shown that a Sost null mutation partially rescues the Lrp6+/2
skeletal phenotype in Sost2/2;Lrp6+/2 animals [36].
Whereas both prostaglandins and Wnt signaling have parallel
functions during bone anabolism, there is limited evidence for
cross-talk between these two signaling pathways in pre-osteoblasts
and in transformed cells. In this study, we examined the influence
of PGE2 on Sclerostin transcription and Wnt signaling, in
osteoblastic cells. We demonstrate that prostaglandin E2, a long-
recognized regulator of osteoblast and osteoclast formation
activity, decreases Sost expression and thereby increases Wnt
signaling in osteoblastic cells. We also show that PGE2
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transcriptional effect on Sost is mediated through the EP2 receptor
(Ptger2) and cAMP, and involves mitigation of endogenous BMP
and Mef2 signaling. These results attribute a novel function of
prostaglandins in the regulation of Wnt signaling via suppression of
the Wnt antagonist Sclerostin.
Results
Prostaglandin E2 decreases Sost transcription
Although both prostaglandins and Wnt signaling have been
characterized as robust regulators of skeletal formation and
homeostasis [9,24,46,47,48], there is sparse evidence whether
there is direct interaction between these pathways. To that end, we
first sought whether PGE2 demonstrated an effect upon the
transcription of Sclerostin. To test this, UMR106.01 cells were
chosen, as they phenotypically resemble mature osteoblasts and
express high levels of Sost [43,50,51]. UMR106.01 cells were
treated with 5 nM–5 mM PGE2 for 3 hours, after which time
RNA was collected and analyzed via quantitative PCR (qPCR) for
Sost expression. There was no influence of 5 nM PGE2 on Sost
expression, while there was steady and progressive decrease in Sost
levels upon 50 nM–5 mM PGE2 treatment (Figure 1A). This
inhibitory effect upon Sost was not observed when cells were
treated with another osteotropic prostaglandin, PGF2a (5 nM–
5 mM; data not shown). The inhibitory effect of PGE2 was rapid,
with statistically significant suppression of Sost observed after one
hour of treatment, and this was maintained throughout 24 hours
of culture (Figure 1B).
Prostaglandin E2 influences Wnt signaling without
affecting Dkk1
Functional decrease in the expression of the Wnt antagonist Sost
should effectively increase markers of b-catenin/TCF signaling,
such as Axin2 and Tcf3. To that end, we observed that PGE2, in
the same dosing range that decreased Sost, significantly increased
Axin2 and Tcf3 expression after 24 hour culture (Figure 2A),
suggesting that PGE2-induced decreases in Sost removed a
suppressive effect of endogenous Wnt antagonists upon osteoblast
function. Dickkopf1 (Dkk1) inhibits Wnt signaling in the same
manner as does Sclerostin [42]. Whereas 50 nM–5 mM PGE2
dramatically reduced Sost transcript and protein (not shown) levels,
PGE2 had no effect on Dkk1 transcript (Figure 2B) nor its protein
(Figure 2C) expression, suggesting that Sost repression is the
primary mechanism of enhanced Wnt signaling in response to
PGE2 treatment.
PGE2 decreases Sost through cAMP-dependent
mechanisms
UMR 106.01 cells express all four classes of PGE2 receptors
(EP1–EP4, encoded by Ptger1–Ptger4; Figure 3A), which are linked
to the synthesis or mobilization of cAMP and Ca2+i. EP2 and EP4
increase cAMP levels, while EP1 increases Ca2+i through a PLC-
dependent mechanism; EP3 increases Ca2+i and decreases cAMP
[52]. To define which receptor(s) are responsible for mediating the
suppressive effects of PGE2 upon Sost, UMR 106.01 cells were
treated with 5 mM PGE2 in the presence of antagonists of protein
kinase A (H-89, 2.5 mM) or phospolipase C (U73122, 10 mM) for
3 hours, after which time total RNA was collected and analyzed
for Sost levels. In the absence of PGE2, inhibition of PLC/IP3/
Ca2+i signaling decreased basal Sost levels (Figure 3B), suggesting
that release of intracellular calcium is important for maintaining
Sost expression. In the presence of PGE2, the addition of H-89
appeared to attenuate PGE2-induced Sost suppression (Figure 3B)
although this did not reach statistical significance (p,0.1 versus
5 mM PGE2 alone). In contrast, the addition of PGE2 to U73122-
treated cells demonstrated no change compared to U73122 alone.
The role of cAMP and Ca2+i mobilization in suppressing Sost was
tested using selective agonists. UMR106.01 cells treated with the
cAMP mimetic 8-bromo-cAMP (1 mM) demonstrated similar
suppression of Sost as 5 mM PGE2-treated cells (Figure 3C),
whereas 1.3 mM ionomycin treatment significantly increased Sost
expression. These data indicate that PGE2 receptors linked to
increased cAMP—Ptger2 or Ptger4—are involved in the capacity
for PGE2 to decrease Sost.
Specific agonists for EP2 (butaprost, [53]) or EP4 (CAY10580,
[54]) were also tested for their ability to mimic the suppressive
effects of PGE2 on Sost transcription. Butaprost mimicked the
ability of PGE2 to decrease Sost, whereas CAY10580 had no effect
on Sost levels (Figure 4A). siRNA directed against Ptger2
(Figure 4B) or Ptger4 (Figure 4C) reproducibly decreased target
transcript expression by 60% relative to non-silencing, scrambled
siRNAs. Knock-down of Ptger2, but not Ptger4, significantly
impaired the ability of PGE2 to suppress Sost expression
(Figure 4D), indicating the requirement for the Ptger2 receptor
for PGE2-specific activation of Wnt signaling.
Figure 1. PGE2 decreases Sost expression. (A) Human PTH(1–34)
(100 nM) or PGE2 (5 nM–5 mM) or vehicle control (0.05% DMSO) was
added to UMR 106.01 cells for 3 hours. Total RNA was collected and
analyzed for Sost and Rpl32 expression by qPCR. n = 6–10 samples per
treatment. a indicates p,0.05 versus Control; b indicates P,0.05 versus
5 nM PGE2. (B) Sost mRNA expression was quantified in UMR 106.01
cells after 0, 1, 2, 3, 6, or 24 hours treatment with 5 mM PGE2 or vehicle
control. n = 4 samples per treatment. For PGE2, each time point is
significantly different (p,0.05) from Control, while for PTH, every time
point except 1 hr is significantly different (p,0.05) from Control.
doi:10.1371/journal.pone.0017772.g001
PGE2 Decreases Sost in Osteoblasts
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Cycloheximide, but not Actinomycin D, influences PGE2
suppression of Sclerostin
We examined the transcriptional and translational mechanisms
whereby PGE2 regulates Sost expression. UMR106.01 cells were
treated with 5 mM PGE2 for 3 hours in the presence or absence of
the RNA polymerase II inhibitor Actinomycin D (2.5 mg/mL),
after which time total RNA was collected and analyzed. The
suppressive influence of PGE2 on Sost transcription was consistent
in cells treated with or without actinomycin D (Figure 5A),
indicating that PGE2 does not promote the degradation of Sost
transcript.
Next, UMR106.01 cells were treated with or without 5 mM
PGE2 for 3 hours in the presence or absence of the protein
translation inhibitor cycloheximide (CHX; 10 mg/mL). In the
absence of PGE2, CHX increased Sost transcript (Figure 5B); in
cells treated with PGE2 and CHX, there was no suppressive effect
of PGE2 upon Sost expression, indicating that PGE2 requires de
novo protein synthesis in order to decrease Sost. Similar results were
observed after 1 hour of CHX or PGE2 treatment (data not shown).
Transcriptional regulation of Sost by PGE2 does not
involve Mef2 or BMPs
We have previously demonstrated that the MEF2 family of
transcription factors are responsible for sensitizing the Sost distal
enhancer ECR5 to PTH [45]. We employed siRNA against Mef2c
or Mef2d in order to determine whether these transcription factors
are involved in the capacity for PGE2 to decrease Sost. 48 hours
after transfection, expression of Mef2c (Figure 6A) and Mef2d
(Figure 6B) was reduced approximately 70% and 55%,
respectively, compared to scrambled siRNA controls. Knock-
down of Mef2c or Mef2d did not alter the ability of 5 mM PGE2 to
decrease Sost transcript (Figure 6C), suggesting that PGE2 does
not decrease Sost expression by disrupting Mef2 activity.
We, and others, have previously demonstrated the transcrip-
tional influence of bone morphogenetic proteins on Sost:
exogenous BMPs or constitutively-active BMP receptor 1A
increase Sost expression [50,51,55], whereas dominant-negative
BMP Receptor 1A decreases Sost transcription [55]. To examine
whether PGE2 signaling disrupted BMP induction of Sost,
UMR106.01 cells co-cultured with 5 mM PGE2 and BMP-2 (0–
500 ng/mL) for 3 hours. BMP-2-treated cells increased Sost
expression (Figure 7A), whereas co-culture with PGE2 prevented
Sost induction. BMP-2 increased Id1, a direct Smad target gene,
independent of PGE2 (Figure 7B), indicating that BMP signaling
was unaffected by PGE2 treatment. These data suggest that PGE2
decreases Sost transcription independent of the BMP signaling, and
hence the effect of PGE2 upon Sost is downstream of BMPs.
PTH does not require prostaglandins to decrease Sost
PTH increases COX-2 expression and subsequent synthesis and
release of prostaglandins [56,57]. Because both PTH and PGE2
decrease Sost transcription through cAMP/PKA mechanisms, we
next examined whether the capacity for PTH to decrease Sost
required prostaglandins. Cells were treated for 24 hours in
reduced serum (2%) conditions in the presence of 0.05% DMSO
or 1 mM indomethacin; thereafter, a subset of cells were treated for
24 hours in the presence of 100 nM hPTH(1–34). As shown in
Figure 8, there was a similar decrease in Sost expression in cells
treated with PTH with or without indomethacin co-treatment.
Thus, PTH does not require prostaglandins to decrease Sost
transcription, suggesting that PTH and PGE2 function through
independent, parallel pathways that converge upstream of
Sclerostin’s transcriptional regulation.
Figure 2. PGE2 increases Wnt signaling without affecting Dkk1.
(A) PGE2 (5 nM–5 mM) or vehicle control (0.05% DMSO) was added to
UMR 106.01 cells for 24 hours. Total RNA was collected and analyzed for
Axin2, Tcf3, and Rpl32 expression by qPCR. n = 4 samples. Compared to
vehicle control, a indicates p,0.05. (B) Human PTH(1–34) (100 nM) or
PGE2 (50 nM–5 mM) or vehicle control (0.05% DMSO) was added to UMR
106.01 cells for 3 hours. Total RNA was collected and analyzed for Dkk1
and Rpl32 expression by qPCR. n = 8 samples. Compared to vehicle
control, a indicates p,0.05.
doi:10.1371/journal.pone.0017772.g002
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Discussion
Sclerostin is a robust inhibitor of bone formation, such that its
absence leads to increased bone formation, and in high amounts it
causes bone loss. Thus, regulation of its expression, as well as that
of other potent skeletally anabolic or catabolic proteins, is under
intensive investigation as a therapy for those afflicted with
osteoporosis, or as a means of hastening fracture repair. Indeed,
a monoclonal antibody which inhibits Sclerostin function has
already been shown to increase bone formation and strength in
ovariectomized rats beyond that of non-ovariectomized controls
[58] and in aged male rats [59]. Despite its clinical importance in
an aging population, the molecular mechanisms controlling
Sclerostin expression are only beginning to be unraveled
[43,45]. Within this work, we demonstrate that PGE2, a paracrine
signaling agent with diverse effects on skeletal homeostasis,
decreases Sost transcription through the EP2 receptor subclass
(encoded by Ptger2). Reductions in Sost transcription by PGE2 was
shown to involve cAMP and PKA, de novo protein synthesis, and to
occur independently of BMP or MEF2 signaling.
PGE2 decreases Sost expression via PKA and Ptger2
We observed rapid suppression of Sost by PGE2 between
50 nM–5 mM, with a calculated IC50 of 41 nM (data not shown).
Reductions in Sost transcript in response to PGE2 were rapid,
occurring within 1 hr of PGE2 addition, and were sustained,
remaining at 30% expression compared to vehicle-treated samples
after 24 hours of culture. These results are similar to in vivo
calvarial and in vitro cell culture models treated with PTH [43], as
well as murine models of constitutively-active PTHR1 receptor
[44,60].
Osteoblastic cells express all Ptger receptor genes [61,62],
suggesting that PGE2 can exert biological effects through both
cAMP and Ca2+i signaling pathways. Much of the anabolic effect
of PGE2 is mediated through cAMP via EP2 and EP4 [63]. The
cAMP analogue 8-bromo-cAMP mimicked the effect of PGE2
upon Sost transcription. Inhibition of PLC/IP3 with U73122 did
not prevent PGE2 from decreasing Sost, indicating that this
pathway is not obligate. Interestingly, the calcium ionophore,
ionomycin, significantly increased Sost transcription nearly 5-fold
over vehicle controls after 3 hours of treatment. This would
suggest stimulation of MEF2 transcriptional activity in response to
increased Ca2+i, as has been shown in skeletal muscle fibers
[64,65]. Keller and Kneissel have shown a modest decrease in Sost
transcription in response to a similar dose of ionomycin [43], but
they measured Sost levels after 24 hours of ionomycin treatment
(rather than 3 hours, as in the study herein). Whether these
contrasting results are due to timing of ionomycin treatment, or
are secondary to prolonged cellular stress due to supra-physiologic
Ca2+i [66], remains to be elucidated.
Figure 3. PGE2 receptor expression and influence of PGE2 selective agonists upon Sost expression. (A) UMR106.01 cells analyzed for
Ptger1, Ptger2, Ptger3, and Ptger4 transcript expression by qPCR. Data are normalized to Rpl32. n = 4 samples. (B) UMR106.01 cells were cultured with
DMSO as vehicle control, 100 nM hPTH(1–34), 5 mM PGE2 in the presence and absence of inhibitors of protein kinase A (H-89, 2.5 mM) or
phospholipase C (U73122, 10 mM), for 3 hours. Total RNA was analyzed for Sost and normalized to Rpl32. n = 4–8 samples. Compared to solvent
control, a indicates p,.001 and b indicates p,0.05; c indicates p,.001. (C) UMR106.01 cells were cultured with DMSO as vehicle control, 100 nM
hPTH(1–34), the cell-permeant cyclic AMP analogue 8-br-cAMP (1 mM) or the calcium ionophore ionomycin (1.3 mM) for 3 hours, after which total
RNA was collected and analyzed for Sost and Rpl32. n = 4–8 samples. Versus Control, a indicates p,0.05, b indicates p,0.01, and c indicates p,0.001.
doi:10.1371/journal.pone.0017772.g003
PGE2 Decreases Sost in Osteoblasts
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The requirement for cAMP/PKA to decrease Sost thus
implicated either EP2 or EP4 receptor. Butaprost, a selective
agonist for EP2 [67], decreased Sost transcription by 70%, whereas
CAY10580, an EP4 agonist [54], had no significant effect upon
Sost levels. The EP2 receptor was further implicated in mediating
the suppressive effects of PGE2, as siRNA directed against Ptger2,
but not scrambled or Ptger4 siRNA, prevented PGE2-induced
decreases in Sost. In total, these data indicate that PGE2 signals
through EP2 to decrease Sost expression.
PGE2 and PTH decrease Sost through parallel pathways
PTH has also been shown to increase COX-2 expression and
PG release [56,57]. Because PTH and PGE2 are both capable of
mobilizing the same second messengers (cAMP and IP3), and
because both PTH and PGE2 decreased Sost transcription through
similar mechanisms involving cAMP and MEF2, we examined
whether PTH required PGE2 (or other PGs) in order to decrease
Sost. Inhibition of COX-1 and COX-2 function with 1 mM
indomethacin increased Sost expression (data not shown), indicating
tonic suppression of Sost by endogenously-produced prostaglan-
dins. Cells treated with both PTH and indomethacin continued to
demonstrate suppression of Sost, indicating that PTH does not
require prostaglandins to decrease Sost levels in mature osteoblastic
cells.
There are several distinctions that must be made regarding Sost
regulation by PTH and PGE2. Keller and Kneissel [43]
demonstrated that PTH rapidly decreases Sost expression in
UMR106.01 cells through a cyclic AMP-dependent pathway.
Leupin et al. identified the MEF2 family of transcription factors as
a requirement for driving bone-specific Sost expression, and as a
target of PTH [45]. Within, we demonstrate that PGE2, like PTH,
decreases Sost in a cyclic AMP-dependent pathway. While PTH
decreases Sost expression through unknown interactions with
MEF2C and MEF2D, we continued to observe Sost suppression in
cells transfected with Mef2c or Mef2d siRNA, demonstrating one
key difference between PGE2 and PTH. Similarly, inhibition of de
novo protein synthesis with cycloheximide maintains PTH
suppression of Sost [43], whereas cycloheximide prevented PGE2
reductions in Sost. These data indicate that, while both PGE2 and
PTH use cAMP to decrease Sost, there is divergence downstream
from cAMP/PKA in the signaling pathways utilized by PTH or
PGE2 for Sost suppression.
Current FDA-approved therapies for combating osteoporosis
are limited to drugs, like bisphosphonates, that inhibit bone
resorption. Intermittent PTH is the only FDA-approved therapy
that promotes bone formation, although treatment is currently
limited to 18 months. The sclerosing bone dysplasias sclerosteosis
and van Buchem disease are caused by decreased or absent
Figure 4. PGE2 signals through Ptger2 to decrease Sost expression. (A) Cells were cultured for 3 hours in the presence of PTH (100 nM), PGE2,
EP2 agonist butaprost, or EP4 agonist CAY10580 (each 500 nM). Sost expression was analyzed by qPCR and normalized to Rpl32. n = 5 samples.
Compared to vehicle control, b indicates p,0.01 and c indicates p,0.001; a indicates p,0.01 versus CAY10580. (B) UMR106.01 cells were cultured
with 50 nM of scrambled or Ptger2 siRNA for 48 hours, after which Ptger2 expression was examined by qPCR. n = 4 samples. Compared to vehicle
control, a indicates p,0.05. (C) UMR106.01 cells were cultured with 50 nM of scrambled or Ptger4 siRNA for 48 hours, after which Ptger4 expression
was examined by qPCR. n = 4 samples. Compared to vehicle control, a indicates p,0.05. (D) UMR106.01 cells were cultured with 50 nM of scrambled,
Ptger2, or Ptger4 siRNA for 48 hours, then with 5 mM PGE2 for 3 hours, after which time total RNA was collected and analyzed for Sost and Rpl32. n = 5
samples. Compared to vehicle control, b indicates p,0.01.
doi:10.1371/journal.pone.0017772.g004
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Sclerostin expression, and thereby implicate Sclerostin as a very
potent inhibitor of bone formation. Thus, mechanisms for
manipulating Sost expression may likely provide a powerful means
of increasing bone mass. Within, we have elucidated a novel
mechanism of Sclerostin regulation. Continued efforts to modulate
its expression and/or activity will likely allow for novel anabolic
agents for conditions of bone loss.
Materials and Methods
Cell culture- UMR106.01 cells, which express phenotypic
markers of mature osteoblasts [68], were cultured in MEM with
Earle’s Salts (Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen) and 1% penicillin and streptomycin (P&S;
Invitrogen). Cells were routinely sub-cultured, using 0.05%
trypsin/EDTA when 80–90% confluent; for experiments, cells
were seeded into 35 mm2 dishes at 5 k/cm2, and experiments
were performed two days thereafter.
Chemicals and reagents- PGE2 and PGF2a (Cayman
Chemical) were dissolved in DMSO as stock concentrations of
10 mM. Human PTH(1–34) (Bachem) was dissolved in
HBSS+0.1% BSA and stored at 100 mM aliquots. H-89 or 8-br-
cAMP (EMD Biosciences) were dissolved in sterile water; U73122,
ionomycin (both EMD Biosciences), butaprost, or CAY10580
(both Cayman Chemical) were dissolved in DMSO.
Quantitative PCR- At the indicated time, cells were washed
with PBS and total RNA was collected using RNeasy Mini kit
(Qiagen). Total RNA (200–1000 ng) was reverse-transcribed with
QuantiTect Reverse Transcription Kit (Qiagen), which includes a
genomic DNA elimination step. qPCR was performed using
QuantiFast Probe PCR Kit (Qiagen) on a MastercyclerH realplex2
(Eppendorf). Proprietary primer and TaqMan probe sets were
purchased from Applied Biosystems. Amplification conditions
Figure 5. Effects of actinomycin D or cycloheximide upon PGE2
suppression of Sclerostin. (A) UMR106.01 cells were serum-starved
for 1 hour, treated with 2.5 mg/mL actinomycin D with or without 5 mM
PGE2, and collected 3 hours later. cDNA was prepared for qPCR analysis
of Sost and Rpl32. n = 4 samples. (B) UMR 106.01 cells were treated with
combinations of 10 mg/mL cycloheximide and 5 mM PGE2 for 3 hours.
Samples were analyzed by qPCR for Sost and Rpl32. n = 4 samples.
Compared to vehicle control, a indicates p,0.05 and b indicates
p,0.001; compared to 5 mM PGE2, c indicates p,0.001.
doi:10.1371/journal.pone.0017772.g005
Figure 6. Reductions in MEF2 expression do not impair PGE2
decrease of Sost. (A) UMR106.01 cells were cultured with 50 nM of
scrambled or Ptger4 siRNA for 48 hours, after which Mef2c expression
was examined by qPCR. n = 4 samples. Compared to scrambled control,
c indicates p,0.001. (B) UMR106.01 cells were cultured with 50 nM of
scrambled or Ptger4 siRNA for 48 hours, after which Mef2d expression
was examined by qPCR. n = 4 samples. Compared to scrambled control,
c indicates p,0.01. (C) UMR106.01 cells were cultured with 50 nM of
scrambled, Mef2c, or Mef2d siRNA for 48 hours, then with 5 mM PGE2 for
3 hours, after which time total RNA was collected and analyzed for Sost
and Rpl32. n = 5 samples. Compared to target siRNA control, b indicates
p,0.01 and c indicates p,0.001.
doi:10.1371/journal.pone.0017772.g006
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were 95uC for 3 minutes, followed by 40 cycles at 95uC for
3 seconds and 60uC for 30 seconds. Quantitative PCR results
were normalized to loading control (Rpl32 or Tbp) transcript level
to yield DCt, then normalized to control conditions to generate
DDCt. Relative or fold change in expression was subsequently
calculated using the formula 22DCt or 22DDCt, as described in [69].
Dkk1 ELISA- For measurement of Dkk1 protein production,
cells were prepared as described above and cultured for 24 hours
in 0.05% DMSO or 5 mM PGE2. Conditioned media and whole
cell protein lysates were collected and frozen at 220 C until
analysis. Dkk1 protein levels in conditioned media were analyzed
using a commercially available ELISA against murine Dkk1 (R &
D Systems), and results were normalized to whole cell protein
concentration.
siRNA- small, interfering RNA against Ptger2, Ptger4,Mef2c, and
Mef2d was purchased from Qiagen, as was scrambled, non-
silencing control. Cells were seeded at a density of 40,000 cells per
well in a 24-well plate in media supplemented with 10% FBS and
1% P/S. 30 minutes thereafter, 50 nM scrambled, non-silencing
or Ptger2 was prepared with HiperFect (Qiagen) in 100 mL of
serum- and antibiotic-free media. 20 minutes later, siRNA/
HiperFect/media was overlayed on top of the cells, which were
returned to the incubator. Experiments were performed 48 hours
later.
Statistical analysis- Each data set was acquired a minimum
of three times, in duplicate. qPCR data were first analyzed relative
to the internal control Rpl32, then normalized to vehicle control,
in order to minimize inter-experimental variation. Results are
expressed as mean6standard error of the mean. Data were
analyzed by Kruskal–Wallis or ANOVA followed by Dunnet or
Tukey post-hoc tests where appropriate. p,0.05 was considered
statistically significant.
Author Contributions
Conceived and designed the experiments: DCG CEY GGL. Performed the
experiments: DCG. Analyzed the data: DCG GGL. Contributed reagents/
materials/analysis tools: DCG CEY GGL. Wrote the paper: DCG CEY
GGL.
References
1. Feyen JH, Di Bon A, van der Plas A, Lowik CW, Nijweide PJ (1985) Effects of
exogenous prostanoids on the proliferation of osteoblast-like cells in vitro.
Prostaglandins 30: 827–840.
2. Hakeda Y, Yoshino T, Natakani Y, Kurihara N, Maeda N, et al. (1986)
Prostaglandin E2 stimulates DNA synthesis by a cyclic AMP-independent
pathway in osteoblastic clone MC3T3-E1 cells. J Cell Physiol 128: 155–161.
3. Minamizaki T, Yoshiko Y, Kozai K, Aubin JE, Maeda N (2009) EP2 and EP4
receptors differentially mediate MAPK pathways underlying anabolic actions of
prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone 44:
1177–1185.
4. Hakeda Y, Nakatani Y, Hiramatsu M, Kurihara N, Tsunoi M, et al. (1985)
Inductive effects of prostaglandins on alkaline phosphatase in osteoblastic cells,
clone MC3T3-E1. J Biochem 97: 97–104.
5. Flanagan AM, Chambers TJ (1992) Stimulation of bone nodule formation in
vitro by prostaglandins E1 and E2. Endocrinology 130: 443–448.
6. Klein-Nulend J, Burger EH, Semeins CM, Raisz LG, Pilbeam CC (1997)
Pulsating fluid flow stimulates prostaglandin release and inducible G/H synthase
mRNA expression in primary mouse bone cells. J Bone Miner Res 12: 45–
51.
7. Chen NX, Ryder KD, Pavalko FM, Turner CH, Burr DB, et al. (2000) Calcium
regulates fluid shear-induced cytoskeletal reorganization and gene expression in
osteoblasts. Am J Physiol 278: C989–997.
8. Wadhwa S, Godwin SL, Peterson DR, Epstein MA, Raisz LG, et al. (2002) Fluid
flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent
on an extracellular signal-regulated kinase signaling pathway. J Bone Miner Res
17: 266–274.
Figure 7. PGE2 decreases Sost without affecting BMP signaling.
(A) Cells were treated with BMP-2 (0–500 ng/mL) in the presence or
absence of 5 mM PGE2 for 3 hours, after which (A) Sost or (B) Id1
expression was monitored. Compared to vehicle control, a indicates
p,0.05 and b indicates p,0.01; compared to BMP-2 without PGE2; , c
indicates p,0.001.
doi:10.1371/journal.pone.0017772.g007
Figure 8. PTH decreases Sost expression independent of
prostaglandins. Cells were exposed to 1 mM indomethacin for
24 hours, then treated with 100 nM hPTH(1–34) or vehicle control for
24 further hours. Sost expression was analyzed by qPCR and normalized
to Rpl32. Compared to vehicle or indomethacin control, a indicates
p,0.05.
doi:10.1371/journal.pone.0017772.g008
PGE2 Decreases Sost in Osteoblasts
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17772
9. Pead MJ, Lanyon LE (1989) Indomethacin modulation of load-related
stimulation of new bone formation in vivo. Calcif Tissue Int 45: 34–40.
10. Forwood MR (1996) Inducible cyclo-oxygenase (COX-2) mediates the induction
of bone formation by mechanical loading in vivo. J Bone Miner Res 11:
1688–1693.
11. Jee WS, Ma YF (1997) The in vivo anabolic actions of prostaglandins in bone.
Bone 21: 297–304.
12. Gerstenfeld LC, Einhorn TA (2004) COX inhibitors and their effects on bone
healing. Expert Opin Drug Saf 3: 131–136.
13. Simon AM, Manigrasso MB, O’Connor JP (2002) Cyclo-oxygenase 2 function is
essential for bone fracture healing. J Bone Miner Res 17: 963–976.
14. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, et al.
(2000) Nonunion of the femoral diaphysis. The influence of reaming and non-
steroidal anti-inflammatory drugs. J Bone Joint Surg Br 82: 655–658.
15. Burd TA, Hughes MS, Anglen JO (2003) Heterotopic ossification prophylaxis
with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg
Br 85: 700–705.
16. Li M, Ke HZ, Qi H, Healy DR, Li Y, et al. (2003) A novel, non-prostanoid EP2
receptor-selective prostaglandin E2 agonist stimulates local bone formation and
enhances fracture healing. J Bone Miner Res 18: 2033–2042.
17. Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, et al. (2003) An
EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl
Acad Sci U S A 100: 6736–6740.
18. Axelrad TW, Kakar S, Einhorn TA (2007) New technologies for the
enhancement of skeletal repair. Injury 38 Suppl 1: S49–62.
19. Cameron KO, Lefker BA, Ke HZ, Li M, Zawistoski MP, et al. (2009) Discovery
of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that
induces local bone formation. Bioorg Med Chem Lett 19: 2075–2078.
20. Bodine PV, Komm BS (2006) Wnt signaling and osteoblastogenesis. Rev Endocr
Metab Disord 7: 33–39.
21. Akiyama T (2000) Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 11:
273–282.
22. Nusse R (1999) WNT targets. Repression and activation. Trends Genet 15: 1–3.
23. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL
receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Cell 107: 513–523.
24. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, et al. (2002) A
mutation in the LDL receptor-related protein 5 gene results in the autosomal
dominant high-bone-mass trait. Am J Hum Genet 70: 11–19.
25. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, et al. (2002) Cbfa1-
independent decrease in osteoblast proliferation, osteopenia, and persistent
embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell
Biol 157: 303–314.
26. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH,
et al. (2004) Decreased BMD and limb deformities in mice carrying mutations in
both Lrp5 and Lrp6. J Bone Miner Res 19: 2033–2040.
27. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, et al. (2006) The Wnt Co-
receptor LRP5 is essential for skeletal mechanotransduction but not for the
anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:
23698–23711.
28. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, et al. (2004) The Wnt
antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular
bone formation in adult mice. Mol Endocrinol 18: 1222–1237.
29. Bodine PV, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, et al. (2005)
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and
osteocyte apoptosis. J Cell Biochem 96: 1212–1230.
30. Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ,
et al. (1999) Localization of the gene for sclerosteosis to the van Buchem disease-
gene region on chromosome 17q12-q21. Am J Hum Genet 64: 1661–1669.
31. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, et al. (2001) Increased
bone density in sclerosteosis is due to the deficiency of a novel secreted protein
(SOST). Hum Mol Genet 10: 537–543.
32. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, et al.
(2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a
novel cystine knot-containing protein. Am J Hum Genet 68: 577–589.
33. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted
deletion of the sclerostin gene in mice results in increased bone formation and
bone strength. J Bone Miner Res 23: 860–869.
34. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, et al. (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Embo J 22: 6267–6276.
35. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, et al. (2005) Genomic
deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem
disease. Genome Res 15: 928–935.
36. Collette NM, Genetos DC, Murugesh D, Harland RM, Loots GG (2010)
Genetic evidence that SOST inhibits WNT signaling in the limb. Dev Biol 342:
169–179.
37. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, et al. (2003) Sclerostin is
a novel secreted osteoclast-derived bone morphogenetic protein antagonist with
unique ligand specificity. J Biol Chem 278: 24113–24117.
38. Li X, Zhang Y, Kang H, Liu W, Liu P, et al. (2005) Sclerostin binds to LRP5/6
and antagonizes canonical Wnt signaling. J Biol Chem 280: 19883–19887.
39. Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a
Wnt signaling inhibitor. J Biol Chem 280: 26770–26775.
40. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, et al. (2006) Bone density
ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to
modulate Wnt activity. J Bone Miner Res 21: 1738–1749.
41. Semenov MV, He X (2006) LRP5 mutations linked to high bone mass diseases
cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:
38276–38284.
42. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I,
et al. (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in
bone formation and bone mass. J Bone Miner Res 21: 934–945.
43. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:
148–158.
44. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, et al. (2005) Chronic elevation of
parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a
novel mechanism for hormonal control of osteoblastogenesis. Endocrinology
146: 4577–4583.
45. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, et al. (2007) Control of
the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone
Miner Res 22: 1957–1967.
46. Chyun YS, Raisz LG (1984) Stimulation of bone formation by prostaglandin E2.
Prostaglandins 27: 97–103.
47. Jorgensen HR, Svanholm H, Host A (1988) Bone formation induced in an infant
by systemic prostaglandin-E2 administration. Acta Orthop Scand 59: 464–466.
48. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, et al. (2005)
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:
21162–21168.
49. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, et al.
(2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone
formation. Faseb J 19: 1842–1844.
50. Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC (2009) Modulation of
sclerostin expression by mechanical loading and bone morphogenetic proteins in
osteogenic cells. Biorheology 46: 389–399.
51. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, et al.
(2010) Hypoxia decreases sclerostin expression and increases Wnt signaling in
osteoblasts. J Cell Biochem 110: 457–467.
52. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282:
11613–11617.
53. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, et al. (1997)
Ligand binding specificities of the eight types and subtypes of the mouse
prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol
122: 217–224.
54. Billot X, Chateauneuf A, Chauret N, Denis D, Greig G, et al. (2003) Discovery
of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med
Chem Lett 13: 1129–1132.
55. Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, et al. (2008) BMP
signaling negatively regulates bone mass through sclerostin by inhibiting the
canonical Wnt pathway. Development 135: 3801–3811.
56. Kawaguchi H, Raisz LG, Voznesensky OS, Alander CB, Hakeda Y, et al. (1994)
Regulation of the two Prostaglandin G/H Synthases by parathyroid hormone,
interleukin-1, cortisol, and prostaglandin E2 in cultured neonatal mouse
calvariae. Endocrinology 135: 1157–1164.
57. Maciel FM, Sarrazin P, Morisset S, Lora M, Patry C, et al. (1997) Induction of
cyclooxygenase-2 by parathyroid hormone in human osteoblasts in culture.
J Rheumatol 24: 2429–2435.
58. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, et al. (2009) Sclerostin
antibody treatment increases bone formation, bone mass, and bone strength in a
rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578–588.
59. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, et al. (2010)
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone
mass and bone strength in aged male rats. J Bone Miner Res.
60. O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, et al. (2008) Control
of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS
ONE 3: e2942.
61. Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, et al. (1996) Prostaglandin E
receptor subtypes in mouse osteoblastic cell line. Endocrinology 137:
1698–1705.
62. Lee CM, Genetos DC, You Z, Yellowley CE (2007) Hypoxia regulates PGE(2)
release and EP1 receptor expression in osteoblastic cells. J Cell Physiol 212:
182–188.
63. Blackwell KA, Raisz LG, Pilbeam CC (2010) Prostaglandins in bone: bad cop,
good cop? Trends Endocrinol Metab 21: 294–301.
64. Wu H, Naya FJ, McKinsey TA, Mercer B, Shelton JM, et al. (2000) MEF2
responds to multiple calcium-regulated signals in the control of skeletal muscle
fiber type. EMBO J 19: 1963–1973.
65. Blaeser F, Ho N, Prywes R, Chatila TA (2000) Ca(2+)-dependent gene
expression mediated by MEF2 transcription factors. J Biol Chem 275: 197–209.
66. Hamamura K, Liu Y, Yokota H (2008) Microarray analysis of thapsigargin-
induced stress to the endoplasmic reticulum of mouse osteoblasts. J Bone Miner
Metab 26: 231–240.
67. Gardiner PJ (1986) Characterization of prostanoid relaxant/inhibitory receptors
(psi) using a highly selective agonist, TR4979. Br J Pharmacol 87: 45–56.
PGE2 Decreases Sost in Osteoblasts
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17772
68. Partridge NC, Alcorn D, Michelangeli VP, Ryan G, Martin TJ (1983)
Morphological and biochemical characterization of four clonal osteogenic
sarcoma cell lines of rat origin. Cancer Res 43: 4308–4314.
69. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
PGE2 Decreases Sost in Osteoblasts
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17772
